Uquifa is the API division of Vivimed Labs. Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operates under cGMP conditions and has been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

news image

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

news image

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More

Industry Outlook

CRESILON RECEIVES FIRST FDA CLEARANCE FOR HUMAN USE OF HEMOSTATIC GEL TECHNOLOGY

PRNewswire. | July 03, 2023

news image

Cresilon, Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ("CHG™"). This marks Cresilon's first FDA clearance for human use, validating its revolutionary hemostatic gel technology and the company's global mission to transform wound care. CHG™ util...

Read More

MedTech

APPLIED STEMCELL ANNOUNCES THE EXPANSION OF ITS CGMP MANUFACTURING FACILITY TO SUPPORT CELL AND GENE THERAPY

Applied StemCell Inc. | August 30, 2022

news image

Applied StemCell, Inc. a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/Q...

Read More
news image

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More
news image

Industry Outlook

CRESILON RECEIVES FIRST FDA CLEARANCE FOR HUMAN USE OF HEMOSTATIC GEL TECHNOLOGY

PRNewswire. | July 03, 2023

Cresilon, Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ("CHG™"). This marks Cresilon's first FDA clearance for human use, validating its revolutionary hemostatic gel technology and the company's global mission to transform wound care. CHG™ util...

Read More
news image

MedTech

APPLIED STEMCELL ANNOUNCES THE EXPANSION OF ITS CGMP MANUFACTURING FACILITY TO SUPPORT CELL AND GENE THERAPY

Applied StemCell Inc. | August 30, 2022

Applied StemCell, Inc. a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/Q...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us